Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001104659-25-087113
Filing Date
2025-09-03
Accepted
2025-09-03 17:17:56
Documents
6

Document Format Files

Seq Description Document Type Size
1 DEFM14A tm2523908-2_defm14a.htm DEFM14A 2648103
2 GRAPHIC lg_lavanv-4c.jpg GRAPHIC 11821
3 GRAPHIC ic_boardarrow-bw.jpg GRAPHIC 1379
4 GRAPHIC lg_leerinkpartners-4c.jpg GRAPHIC 11632
5 GRAPHIC px_25lavapy01pg01-bw.jpg GRAPHIC 243343
6 GRAPHIC px_25lavapy01pg02-bw.jpg GRAPHIC 181116
  Complete submission text file 0001104659-25-087113.txt   3207744
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-40241 | Film No.: 251290997
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)